WAYNE, N.J., Jan. 29 (UPI) -- Berlex said Monday the U.S. Food and Drug Administration approved its oral contraceptive Yaz for treating acne.
Berlex, an affiliate of Bayer Schering, said the new indication is for treating moderate acne vulgaris in women who desire an oral contraceptive for birth control.
"This latest regulatory approval underscores the culmination of years of research that confirms the promise of YAZ and the distinctness of our innovative progestin, drospirenone, in delivering benefits that are beyond reliable birth control," said Reinhard Franzen, Berlex's president and chief executive officer.
The approval makes Yaz the first and only oral contraceptive ever approved for three indications. In addition to being approved as birth control, the FDA approved Yaz last year for treating the emotional and physical symptoms associated with premenstrual dysphoric disorder.
